Sinovac GAAP net loss widens to $60.2 million in 1H FY26; sales rise 12.9% to $147.1 million
SVA•SVA•SVA•SVA•Sinovac posted H1 2026 sales of USD 147.1 million, up 12.9% from the prior-year period.
Net loss attributable to common shareholders widened to USD 60.2 million, or USD 0.84 per share.
Gross profit rose to USD 95.5 million; gross margin improved 2.5 percentage points to 65%.
Overseas revenue more than doubled to USD 66.5 million, up 82.3%, representing 45.2% of total sales.
CEO Weidong Yin said the rabies vaccine PVRV-SF won NMPA approval on Aug. 4, 2026; a WHO PQ filing is planned.
